European Commission Approves Trizivir for Sales in EU
The European Commission has given approval to British pharmaceutical company GlaxoSmithKline to market its HIV drug Trizivir in all 15 member states of the European Union. This follows the November FDA approval of the drug, which combines three anti-HIV therapies in one pill. The drug, developed by the Canadian firm BioChem, is expected to bring in sales of $260 million this year with 13% to 14% going to BioChem in royalty payments. An application for Trizivir was submitted to the European Medicines Evaluation Agency in December 1999. The drug is already sold in the United States, Mexico, Switzerland, Ghana, Chile and Malawi (Reuters/Excite News, 1/4).This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.